Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | The impact of high-dose melphalan on myeloma-related mutations & risk level

Nathan Sweeney • 17 May 2022
COMy 2022
Multiple Myeloma Melphalan

Nathan Sweeney, PhD, HealthTree, Lehi, UT, briefly discusses a study which investigated whether receiving high-dose melphalan would increase mutation burden and risk level in myeloma patients. Dr Sweeney discusses some results from this study and the impact of both high-dose melphalan and standard chemotherapy on disease burden. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Nathan Sweeney

2:56
Insights into the HealthTree foundation
Nathan Sweeney • 17 May 2022
3:57
Updates from a study investigating exposure to pesticides and the risk of developing myeloma
Nathan Sweeney • 17 May 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals